Vasorum Limited has announced the appointment of Bob Smouse as a non-executive director.
Vasorum specialises in devices used to close arterial punctures in vascular, cardiology, radiology, and neuroradiology procedures. In February of this year, the company raised €6 million in equity from leading Irish Growth Capital investor BGF. Enterprise Ireland is also a shareholder in the company.
Vasorum developed and markets the Celt arterial closure device (ACD), which is used to close femoral artery punctures. The CELT ACD is a Class III medical device based on a patented platform technology, which was approved by the US Food and Drug Administration (FDA) in 2017, and has been used in over 84,000 patients to date.
Smouse has more than 25 years’ experience in both medical device development and clinical practice and research, he has led many important studies in the USA as a principal investigator and has served as a medical consultant and Scientific Advisory Board member for many medical device industry leaders. Most recently, he was the founder, CEO, and CMO of BrightWater Medical, a US-based medical device company that commercialised a urologic catheter technology. BrightWater Medical was acquired by Merit Medical in 2019.
